Minimum Effective Dosages of Anti-TNF in Rheumatoid Arthritis: A Cross-sectional Study

Agarwal, 2011, Biologic agents in rheumatoid arthritis: an update for managed care professionals, J Manag Care Pharm, 17, S14, 10.18553/jmcp.2011.17.s9-b.S14 Den Broeder, 2002, Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNFalpha, Rheumatology (Oxford), 41, 638, 10.1093/rheumatology/41.6.638 Bendtzen, 2011, Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?, Arthritis Rheum, 63, 867, 10.1002/art.30207 Moots, 2011, Differences in biologic dose-escalation non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice, Clin Exp Rheumatol, 29, 26 Raffeiner, 2010, The effects of low dose etanercept on disease control and radiographic progression in moderate to severe rheumatoid arthritis, Arthritis Rheum, 62, 290 Smolen, 2010, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs, Ann Rheum Dis, 69, 964, 10.1136/ard.2009.126532 Arnett, 1988, The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis, Arthritis Rheum, 31, 315, 10.1002/art.1780310302 Ogale, 2011, Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study, BMC Musculoskelet Disord, 12, 204, 10.1186/1471-2474-12-204 Finckh, 2006, Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis, Ann Rheum Dis, 65, 746, 10.1136/ard.2005.045062 Ariza-Ariza, 2007, Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review, Rheumatology (Oxford), 46, 529, 10.1093/rheumatology/kel326 Rahman, 2007, Double-blinded infliximab dose escalation in patients with rheumatoid arthritis, Ann Rheum Dis, 66, 1233, 10.1136/ard.2006.065995 Durez, 2005, A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study, Rheumatology (Oxford), 44, 465, 10.1093/rheumatology/keh494 Pavelka, 2009, Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy, Ann Rheum Dis, 68, 1285, 10.1136/ard.2008.090860 Van Der Maas, 2012, Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study, Ann Rheum Dis, 71, 1849, 10.1136/annrheumdis-2011-200945 Van Den Bemt, 2008, Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study, Ann Rheum Dis, 67, 1697, 10.1136/ard.2007.083683 Schipper, 2010, Metaanalysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome, Rheumatology (Oxford), 49, 2154, 10.1093/rheumatology/keq195 Soliman, 2011, Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register, Ann Rheum Dis, 70, 583, 10.1136/ard.2010.139774 Yazici, 2008, Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy, Bull NYU Hosp Jt Dis, 66, 77 Mann, 2003, Observational research methods Research design II: cohort, cross sectional and case–control studies, Emerg Med J, 20, 54, 10.1136/emj.20.1.54